VIM and breast carcinoma: On the other hand, lumican treatment of shERβΜDA-MB-231 breast cancer cells revealed a slight increase of the expression levels of the epithelial marker E-cadherin, whereas it decreased that of the mesenchymal marker vimentin (Fig. 5a).